Estimaciones de analistas de Wall Street para Enlivex Therapeutics Ltd. (ENLV): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-12-07 | $-0.28 | ||
| 2026-09-18 | $-0.31 | ||
| 2026-03-30 | $-3.45 | $-0.45 | -666.7% |
| 2026-03-25 | $410.25 | $-1.29 | +31791.8% |
| 2025-11-14 | $-1.35 | $-1.80 | +25.0% |
| 2025-08-29 | $-1.20 | $-2.40 | +50.0% |
| 2025-05-30 | $-2.25 | $-2.40 | +6.2% |
| 2025-03-31 | $-3.45 | $-2.40 | -43.8% |
Ratios de valoración
| Ratio P/E | 0.00 |
| Precio / Valor contable | 0.00 |
| EV / EBITDA | -1.20 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | $2.3M | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $25000 | $12000 | $121000 | $297000 | $286000 | $546000 | $777000 | $835000 | $545000 | $332000 |
| Beneficio Bruto | -$25000 | -$12000 | -$121000 | -$297000 | -$286000 | -$546000 | -$777000 | -$835000 | -$545000 | -$332000 |
| I+D | $8.9M | $2.5M | $4.1M | $5.7M | $6.1M | $12.9M | $18.7M | $19.2M | $10.1M | $8.9M |
| Generales y Administrativos | $7.0M | $3.4M | $1.0M | $2.8M | $3.6M | $6.2M | $6.7M | $6.1M | $4.9M | $5.7M |
| Gastos Operativos | $13.9M | $5.8M | $5.2M | $8.6M | $9.8M | $19.3M | $25.8M | $29.4M | $15.0M | $14.7M |
| Beneficio Operativo | -$13.9M | -$5.8M | -$5.3M | -$8.6M | -$9.8M | -$19.3M | -$25.8M | -$29.4M | -$15.5M | -$15.0M |
| EBITDA | -$15.8M | -$5.9M | -$5.2M | -$8.4M | -$9.5M | -$18.7M | -$25.0M | -$28.2M | -$14.5M | -$14.7M |
| Gastos por Intereses | 0 | 0 | $3000 | $7000 | $6000 | $328000 | $5.3M | $14000 | $13000 | $13000 |
| Beneficio Antes de Impuestos | -$15.8M | -$5.9M | -$4.2M | -$9.4M | -$11.8M | -$14.5M | -$31.1M | -$29.1M | -$15.0M | $1.62B |
| Impuestos | $216000 | $28000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $382.6M |
| Beneficio Neto | -$16.0M | -$5.9M | -$4.2M | -$9.4M | -$11.8M | -$14.5M | -$31.1M | -$29.1M | -$15.0M | $1.24B |
| BPA | $-604.35 | $-215.25 | $-159.45 | $-17.55 | $-15.75 | $-8.10 | $-34.65 | $-23.40 | $-10.95 | $405.60 |
| BPA Diluido | $-604.35 | $-208.20 | $-159.45 | $-17.55 | $-15.75 | $-8.10 | $-34.65 | $-23.40 | $-10.95 | $382.20 |
| Acciones en Circulación (Diluidas) | $26510 | $28549 | $30735 | $576632 | $877947 | $1.2M | $1.2M | $1.2M | $1.4M | $3.2M |
Precio
| Precio | $0.81 |
| Capitalización | $14M |
| Bolsa | NASDAQ |
| País | IL |
Empresas relacionadas: CLGN · CVKD · GDTC · LSTA · MTVA · NCNA · NRSN
Explorar sector: Healthcare · Biotechnology
Más secciones de ENLV: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones